ES2453391B2 - Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis. - Google Patents

Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis. Download PDF

Info

Publication number
ES2453391B2
ES2453391B2 ES201200865A ES201200865A ES2453391B2 ES 2453391 B2 ES2453391 B2 ES 2453391B2 ES 201200865 A ES201200865 A ES 201200865A ES 201200865 A ES201200865 A ES 201200865A ES 2453391 B2 ES2453391 B2 ES 2453391B2
Authority
ES
Spain
Prior art keywords
protein
hemoncosis
production
recombinant
contortus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201200865A
Other languages
English (en)
Other versions
ES2453391A1 (es
Inventor
Jose María ALUNDA RODRIGUEZ
Montserrat CUQUERELLA AYENSA
Elshaima MOHAMED FAWZI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to ES201200865A priority Critical patent/ES2453391B2/es
Priority to PCT/ES2013/000197 priority patent/WO2014037592A1/es
Publication of ES2453391A1 publication Critical patent/ES2453391A1/es
Application granted granted Critical
Publication of ES2453391B2 publication Critical patent/ES2453391B2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis.#Se ha procedido a la obtención de una proteína recombinante (rHc23) de H. contortus tras comprobar que la proteína nativa Hc23, de 23kDa de peso molecular, originaria del extracto soluble de adultos del nematodo hematófago H. contortus ha mostrado capacidad inmunoprotectora en el ganado ovino joven de 5 meses de edad frente a la trichostrongilidosis más importante (hemoncosis) desde un punto de vista económico y patológico.#Se ha caracterizado la proteína Hc23, obteniéndose las secuencias aminoacídicas y genómicas de la misma, permitiendo, por técnicas de biología molecular, ADN recombinante, la producción de una proteína estable, la rHc23. Su utilización en composiciones inmunogénicas que incluyen como adyuvante la combinación de Propionibacterium acnes inactivado + lipopolisacáridos de E. coli ha mostrado un elevado grado de protección en los animales (>85% de protección).

Description



imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17

Claims (1)



  1. imagen1
    imagen2
ES201200865A 2012-09-05 2012-09-05 Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis. Active ES2453391B2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201200865A ES2453391B2 (es) 2012-09-05 2012-09-05 Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis.
PCT/ES2013/000197 WO2014037592A1 (es) 2012-09-05 2013-09-04 Proteína recombinante de haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201200865A ES2453391B2 (es) 2012-09-05 2012-09-05 Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis.

Publications (2)

Publication Number Publication Date
ES2453391A1 ES2453391A1 (es) 2014-04-07
ES2453391B2 true ES2453391B2 (es) 2014-08-14

Family

ID=50236572

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201200865A Active ES2453391B2 (es) 2012-09-05 2012-09-05 Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis.

Country Status (2)

Country Link
ES (1) ES2453391B2 (es)
WO (1) WO2014037592A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110221060B (zh) * 2019-06-23 2021-04-13 南京农业大学 一种用于早期诊断捻转血矛线虫感染的抗原及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747046A (en) * 1989-03-17 1998-05-05 Munn; Edward Albert Vaccine containing a protein complex form Haemonchus contortus
CA2079871A1 (en) * 1991-02-06 1992-08-07 Phillip John Sharp Vaccine
GB0617962D0 (en) * 2006-09-13 2006-10-18 Moredun Res Inst Novel nematode protein and its use in producing anthelminthic agents and vaccines
GB0815674D0 (en) * 2008-08-28 2008-10-08 Moredun Res Inst Nematode vaccine

Also Published As

Publication number Publication date
ES2453391A1 (es) 2014-04-07
WO2014037592A1 (es) 2014-03-13

Similar Documents

Publication Publication Date Title
CY1124592T1 (el) Ζιζανιοκτονως δραστικα 3-φαινυλοïσοξαζολινο-5-καρβοξαμιδια αποτελουμενα απο τετραϋδρο- και διυδροφουρανοκαρβοξυλικα οξεα και εστερες
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
Gasser et al. Understanding Haemonchus contortus better through genomics and transcriptomics
CY1122793T1 (el) Χλωριουχο αλας του tat-nr2b9c
CO2017012893A2 (es) Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
BR112016015422A2 (pt) formulações de vacina de frasco único
DK4097078T3 (da) Aminosyre overfladeaktive midler
PY1548374A (es) Vacunas de FMDV recombinante y usos de las mismas
CY1126231T1 (el) Παραλλαγες ανθρωπινης αλφα-γαλακτοσιδασης
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
DK3471760T3 (da) Hidtil ukendte immunogene formuleringer, der omfatter lineære eller forgrenede polyacrylsyrepolymeradjuvanser
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
EP3528839C0 (en) EXPEC GLYCOCONJUGATE VACCINE FORMULATIONS
MX2015011487A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
MX2016013559A (es) Formulaciones de proteina estables que comprenden un exceso molar de sorbitol.
CL2017002326A1 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
ES2453391B2 (es) Proteína recombinante de Haemonchus contortus y su aplicación para la producción de una vacuna frente a la hemoncosis.
CL2013002631A1 (es) Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2453391

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20140814